SARS-CoV-2 neutralizing antibody bebtelovimab - a systematic scoping review and meta-analysis.

Front Immunol · 2023 · PMC10494534 · PMID 37701439

Europe PMC DOI

hedged sentence

0.0970

closest p · 1.9× alpha

0.0970

boldest claim

The sentences

did not reach statistical significancep = 0.097so close (0.05 < p ≤ 0.1)

In terms of efficacy, bebtelovimab and combination therapy arms had a lower proportion of patients with persistently high viral load at Day 7 but did not reach statistical significance (p = 0.097 for bebtelovimab versus placebo; p = 0.132 for bebtelovimab plus bamlanivimab plus etesevimab versus placebo).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.